苯达莫司汀是一种新的化疗药物，可以增强我们对抗这种疾病的能力。
Bendamustine is a new chemotherapy drug that has expanded the ability to fight this disease.
盐酸苯达莫司汀作为新一代抗癌药物，对多种癌症具有明显的治疗作用。
As a new generation of anti-cancer drugs, bendamustine has an obvious effect on a wide range of cancers.
在向FDA申报批准的临床研究中，大部分病人都对苯达莫司汀和利妥昔单抗耐药。
In the study that led to the FDA approval, most patients were refectory to bendamustine and rituximab.
已报道有关利妥昔单抗的毒性表皮坏死，但毒性表皮坏死和苯达莫司汀的关系尚不确定。
Toxic epidermal necrolysis has been reported for rituximab, but the relationship of toxic epidermal necrolysis to bendamustine has not been determined.
其它恶性的肿瘤被加到警告和注意事项中。苯达莫司汀治疗的病人中有恶性肿瘤和恶性肿瘤前的的报道。
Other malignant neoplasms were added to warnings and precautions, noting reports of premalignant and malignant diseases that developed in patients treated with bendamustine.
2016年2月底，FDA批准了对接受过利妥昔单抗治疗的滤泡性淋巴瘤患者使用抗CD20单抗obinutuzumab和苯达莫司汀联合的方案。
In late February 2016, the FDA approved the anti-CD20 agent obinutuzumab(Gazyva) in combination with bendamustine for patients with follicular lymphoma following rituximab-based therapy.
2016年2月底，FDA批准了对接受过利妥昔单抗治疗的滤泡性淋巴瘤患者使用抗CD20单抗obinutuzumab和苯达莫司汀联合的方案。
In late February 2016, the FDA approved the anti-CD20 agent obinutuzumab(Gazyva) in combination with bendamustine for patients with follicular lymphoma following rituximab-based therapy.
应用推荐